Entering text into the input field will update the search result below

Eli Lilly up 3% premarket on positive selpercatinib data

Sep. 09, 2019 7:06 AM ETEli Lilly and Company (LLY) StockLLY, BPMCBy: Douglas W. House, SA News Editor4 Comments
  • Eli Lilly (NYSE:LLY) is up 3% premarket on light volume in reaction to positive results from a Phase 1/2 clinical trial, LIBRETTO-001, evaluating oral selpercatinib (LOXO-292) as monotherapy in heavily pretreated patients with RET fusion-positive non-small cell lung cancer (NSCLC) who previously received platinum-based chemo. The data were presented at the World Conference on Lung Cancer in Barcelona.
  • The objective response rate (ORR) was 68%. The ORR was 91% in a subset of patients with brain metastases and 85% in treatment-naive patients.
  • At data cutoff, the mean duration of response was 20.3 months and median progression-free survival (PFS) was 18.4 months.
  • On the safety front, the discontinuation rate due to drug-related toxicity was 1.7%. The most common treatment-related adverse events were  dry mouth, diarrhea, hypertension, increased liver enzymes, fatigue, constipation, and headache.
  • Breakthrough Therapy-tagged selpercatinib is a selective RET inhibitor.
  • RET inhibitor-related ticker: Blueprint Medicines (NASDAQ:BPMC).

Recommended For You

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company